Stockholm - Delayed Quote SEK

Abera Bioscience AB (ABERA.ST)

Compare
3.8600 -0.0100 (-0.26%)
At close: 1:46 PM GMT+1

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Mr. Anders Ericsson Executive Chairman of Board -- -- 1970
Ms. Maria Alriksson Chief Executive Officer -- -- 1983
Associate Prof. Joen Luirink Co-Founder & CTO -- -- 1960
Mr. Mats Lundgren VP of Research & Development and CSO -- -- 1965

Abera Bioscience AB

Dragarbrunnsgatan 45
Uppsala, 753 720
Sweden
https://aberabio.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
6

Description

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC, Covid-19, and Tuberculosis. Abera Bioscience AB was incorporated in 2012 and is based in Uppsala, Sweden.

Corporate Governance

Abera Bioscience AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers